China’s Progress in Fertility Medicine

Fertility decisions often involve time, uncertainty and more than one medical question. Some people need a clear diagnosis; others have already completed several treatment cycles and want an independent review. A useful comparison of care in another country begins with the clinical problem, the likely sequence of visits and whether the proposed treatment is actually available to the patient.

China has substantial reproductive medicine infrastructure and has contributed multicentre clinical trials to this field. Its assisted reproductive technologies, including in vitro fertilization (IVF), are regulated. These two facts make China a serious place to evaluate for selected patients, while neither guarantees access to IVF or a live birth. [2][3][5][6]

The World Health Organization estimates that roughly one in six adults experience infertility at some point in life. This is a global lifetime estimate, not a figure for China or for a particular clinic. [1]

An evaluation can identify ovulatory, uterine, tubal, sperm or other factors and help decide whether further testing, treatment of an underlying condition or assisted reproductive technology is appropriate. Depending on history, it may include menstrual and medical history, ultrasound, ovarian reserve measures, semen analysis and assessment of the uterine cavity or tubes. Tests should answer a clinical question; a large fixed panel is not necessarily better. [8][9]

Age and history shape timing. Professional guidance suggests evaluation after 12 months of regular unprotected intercourse for women under 35, after six months for those 35 or older, and sooner for some conditions or for women over 40. These are clinical guideposts, not a rule that every patient must wait. [8]

Anti-Müllerian hormone (AMH) and antral follicle count can help estimate likely ovarian response to stimulation. They do not, alone, measure egg quality or give a reliable prediction of whether a person can conceive naturally. A specialist should interpret them with age, diagnosis and previous treatment response. [8]

Male-factor assessment belongs in the initial plan. The AUA/ASRM guideline recommends concurrent assessment of both partners when applicable, with reproductive history and at least one semen analysis for the male partner. Abnormal findings may warrant an andrology or urology review. [9]

China’s National Health Commission (NHC) publishes a register of institutions approved to perform assisted reproductive technology, with the technologies each institution may provide. The register was updated in November 2025. Approval is specific to the institution and technology; a general fertility consultation and an IVF cycle are not interchangeable services. Confirm the institution’s current approval before making travel plans. [2][3]

A Chinese Society of Reproductive Medicine report collected 1,211,303 assisted reproduction cycles and 470,725 infants across 2013–2016 from 133 reporting centres. At the time, those centres were only part of the national total and reporting was voluntary. The figures demonstrate substantial historical clinical activity, but are not a current national total, an IVF success rate or a forecast for an individual patient. [5]

Chinese centres also contribute controlled trials that test specific decisions within fertility treatment. A trial published in 2026 randomized 4,376 ovulatory women, aged 20–40, across 24 Chinese academic centres before frozen single-blastocyst transfer. Healthy live birth occurred in 910 of 2,185 participants (41.6%) assigned to a natural-ovulation preparation regimen and 890 of 2,191 (40.6%) assigned to a programmed hormone regimen; the difference was not statistically significant. Among patients who achieved a clinical pregnancy, reported pre-eclampsia was 38 of 1,302 (2.9%) versus 61 of 1,326 (4.6%), respectively. Cycle cancellation occurred in 354 of 2,185 (16.2%) versus 251 of 2,191 (11.5%). These results address a defined treatment choice in a selected population; they do not describe the chance of success for all IVF patients or prove that one regimen is best for everyone. [6]

IVF is a sequence, not a single appointment. A potential pathway includes investigation, a treatment decision, ovarian stimulation and monitoring, egg retrieval, laboratory fertilization, embryo culture, a fresh or later frozen transfer, pregnancy testing and ongoing obstetric care. Some patients will need a different pathway, and a cycle may stop before transfer.

For patients with a uterine condition, fibroids or endometriosis, a reproductive surgeon’s opinion may help. Surgery is a decision about the specific condition, symptoms, anatomy and treatment plan; it is not an automatic step before IVF or a guarantee of pregnancy. In endometriosis, European guidance recommends weighing symptoms, age, prior surgery, other infertility factors and ovarian reserve. [10]

“Success rate” is too imprecise for a high-stakes decision. A positive pregnancy test, a clinical pregnancy and a live birth are different outcomes. The denominator may be patients, started cycles, egg retrievals or embryo transfers. Results also change with age, diagnosis, use of patients’ own gametes and prior treatment. For a fuller picture, ask about cumulative live birth following one initiated stimulation cycle, including later transfers of embryos from that cycle, with the time period stated. [12]

Another Chinese multicentre randomized trial illustrates why an additional laboratory step should not be marketed as a universal upgrade. Among 1,212 women aged 20–37 with at least three good-quality blastocysts, cumulative live birth within one year after up to three transfers was 468 of 606 (77.2%) with preimplantation genetic testing for aneuploidy (PGT-A) and 496 of 606 (81.8%) with conventional IVF. This study population had a particularly favourable prognosis. The result does not settle every possible medical indication for genetic testing; it does show why PGT-A should not be sold as a routine route to a higher live-birth chance. Availability and eligibility for any genetic testing must also be checked with an approved institution. [7]

The figures above belong to their respective studies and cannot be compared as competing clinic rates. Ask each provider for results that match your age group, indication and proposed treatment, alongside cancellation, multiple pregnancy and complication data.

Ovarian hyperstimulation syndrome (OHSS) is an uncommon but potentially serious complication of ovarian stimulation. Risk assessment and prevention may change the medication protocol or whether transfer occurs immediately. The ASRM guideline identifies higher ovarian reserve markers, polycystic ovary syndrome and anticipated high egg yield as risk factors and recommends individualizing prevention. [11]

Multiple pregnancy carries additional maternal and infant risks. Discuss the number of embryos proposed for transfer rather than treating twins as a preferred success. Ask how the clinic monitors complications, whom to contact after hours and what happens if symptoms arise after you have returned home. [11][12]

Fertility care can also be emotionally demanding. Repeated testing and unsuccessful cycles may change what a patient wishes to pursue. A credible plan leaves room for counselling, a pause and a review of goals, without treating every unsuccessful step as a reason to buy another procedure.

China’s assisted reproduction rules require these technologies to be performed in approved, registered medical institutions, with informed consent and relevant ethical oversight. The NHC approval list identifies permitted technologies; it does not establish that any named institution will accept a particular international patient. Documentation, eligibility, the exact service and institutional practice must be confirmed directly and in writing before payment or travel. [2][3]

The national management measures prohibit medical institutions and medical personnel from performing surrogacy. Older technical and ethical rules also set restrictions around assisted reproduction. Because law, policy and institutional requirements may change, this page cannot serve as an eligibility ruling for a specific person or a service catalogue for donor arrangements, embryo selection or other sensitive requests. Ask the licensed institution to identify the current legal basis and applicable documents for the proposed pathway. [3][4]

An initial fertility evaluation or second opinion may be possible even when a requested treatment cannot be offered. This is a question to establish with the provider, not a promise of access.

Before committing to travel, ask for a written schedule of appointments and tests, what can be done locally, which visits depend on the menstrual cycle, possible cancellation or extra-cycle costs, and when it is medically appropriate to travel. A short trip may be enough for an opinion; a treatment cycle and later transfer can require a different timetable.

Obtain an itemized estimate covering consultation, testing, medication, monitoring, retrieval, laboratory procedures, transfer, freezing and storage where applicable, and follow-up. Clarify what is charged if a cycle is cancelled or no embryo is available for transfer. Confirm how records and any stored material are handled, including consent, privacy and future decisions.

Arrange a clinician at home for follow-up and early pregnancy care. Ask the Chinese team how urgent concerns will be managed when you are outside the country. The CDC advises patients considering care abroad to plan records, continuity and complications before travel. [13]